Article
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.
European journal of pharmacology - 7 Aug 2006
Kim Kathline, Moore Dan H, Makriyannis Alexandros, Abood Mary E
Abstract excerpt
Effective treatment for amyotrophic lateral sclerosis (ALS) remains elusive. Motor neuron degeneration is the primary pathology in ALS; however non-neuronal cells contribute to the disease process. In particular, inflammatory processes have been shown to play an important role. AM1241 is a cannabinoid CB2 receptor selective agonist that has been shown to be effective in models of inflammation and hyperalgesia....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.